Active Ingredient History
ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wakefulness in adult patients with hypersomnia associated with narcolepsy or obstructive sleep apnoea.The US FDA has approved solriamfetol (Sunosi, Jazz Pharmaceuticals) for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Narcolepsy (approved 2019)
Sleep Apnea, Obstructive (approved 2019)
Attention Deficit Disorder with Hyperactivity (Phase 2/Phase 3)
Binge-Eating Disorder (Phase 4)
Depressive Disorder, Major (Phase 2)
Disorders of Excessive Somnolence (Phase 4)
Fatigue Syndrome, Chronic (Phase 4)
Narcolepsy (Phase 4)
Parkinson Disease (Phase 2)
Postpartum Period (Phase 4)
Sleep Apnea, Obstructive (Phase 4)
Sleep Disorders, Circadian Rhythm (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
